- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Biocon Limited — Updates, 03-08-2026: Press Release
03-08-2026 | 08:28 am
03-08-2026 | 08:28 am
Biocon launched Yesafili™, an interchangeable biosimilar to Eylea® 2 mg, in the U.S. This US FDA-approved product targets ~20 million adults with serious eye conditions, entering a market with over $5.89 billion in annual sales.
No comments yet. Be the first to comment!